Last Modified: May 25, 2005
Conference Dates: August 3-6, 2005
Conference Location: Santa Monica, California
Sponsoring Group: The CBCE
Conference Web Page URL: www.thecbce.com/currentactivities.asp
Topics Covered: Description/Statement of Need: Typically, hematologic malignancies are sensitive to chemotherapy and radiation therapy, but a significant proportion of patients are not cured with traditional treatments. Chemotherapy resistance leads to a pattern of relapse and retreatment, driving the need for improved therapies that increase complete response rates, extend response durations, and eliminate residual disease. Tyrosine kinase inhibitors, such as imatinib, have provided impressive activity in chronic myelogenous leukemia (CML), but resistance to these novel agents is still an issue. In addition, recent data has highlighted the importance of prognostic indicators in the treatment of hematologic malignancies. Patient selection based on these indicators allows physicians to identify and promptly treat patients at the highest risk of rapidly progressive disease. This program will update physicians on the latest advances in the treatment and diagnosis of hematologic malignancies with emphasis on optimizing patient clinical outcome through the use of novel regimens, schedules, and diagnostic techniques.
Conference Objectives: Please see website for further information.
Who Should Attend: This activity is intended for medical oncologists, hematologists, and other health care professionals who treat patients with hematological malignancies.
Conference Agenda: Educational Objectives: After participating in this conference, attendees should be able to:
Registration Information: Registration Website: www.thecbce.com/currentactivities.asp
*A limited number of Scholarships are available for fellows. For consideration and further information, please contact Zack Lentz.
Conference Fees: Please see website for further information.
Continuing Education: Yes
Miscellany: This activity has been approved for AMA Physician’s Recognition Award credits. AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by ACCME.
Dec 14, 2011 - More than two thirds of the venous thromboembolism complications in cancer patients occur in those undergoing outpatient cancer treatment, according to a study being presented at the annual meeting of the American Society of Hematology, held from Dec. 10 to 13 in San Diego.
Dec 14, 2011
Dec 8, 2010
Aug 28, 2014